Evonile Pharma (500672) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
13 Oct, 2026Executive summary
Q1 ended June 30, 2024: revenue was ₹922.9 million and profit for the period was ₹257.4 million, compared with ₹906.0 million and ₹202.6 million in Q1 FY23.
The Board approved the unaudited results after Audit Committee review; statutory auditors completed a limited review.
Financial highlights
Revenue from operations was ₹922.9 million versus ₹906.0 million YoY; total income was ₹1,027.0 million versus ₹1,030.7 million.
Total expenses were ₹690.2 million versus ₹753.0 million; purchases of stock-in-trade were ₹527.3 million versus ₹399.3 million.
Profit before tax was ₹336.8 million versus ₹277.7 million; profit for the period was ₹257.4 million versus ₹202.6 million.
Segment performance
The business operates in one segment: Pharmaceuticals Business.
Latest events from Evonile Pharma
- H1 profit rose YoY despite weaker Q2 revenue and a 54.0 million tax-litigation provision.500672
Q2 24/25 - Q3 revenue grew YoY, while profit declined; 9M net profit edged higher.500672Q3 24/25
- FY25 profit and EPS rose despite lower revenue; INR25/share dividend recommended.500672Q4 24/25
- Q1 profit rose YoY despite lower revenue; cost auditor appointment awaits shareholder ratification.500672Q1 25/26
- Q2 profit rose YoY; H1 profit advanced despite lower revenue.500672Q2 25/26
- Q3 revenue and profit fell YoY as Labour Code costs and tax adjustments shaped results.500672Q3 25/26
- FY26 profit declined; a proposed 70.68% stake sale awaits approvals.500672Q4 25/26
- Q1 revenue and profit rose YoY as a proposed 70.68% ownership transfer advanced.500672Q1 26/27